Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.
Authors
- Rongtao Lai (ORCID: https://orcid.org/0000-0003-1704-7086)
- Ramsey Cheung (ORCID: https://orcid.org/0000-0002-0211-7013)
- Mindie H. Nguyen (ORCID: https://orcid.org/0000-0002-6275-4989)
- Xianhua Mao
- Ka Shing Cheung (ORCID: https://orcid.org/0000-0002-4838-378X)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Xinrong Zhang (ORCID: https://orcid.org/0000-0001-8169-5251)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
Institutions
- Chinese University of Hong Kong (HK)
- Shanghai Jiao Tong University (CN)
- VA Palo Alto Health Care System (US)
- Ruijin Hospital (CN)
- Stanford Medicine (US)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
- Stanford University (US)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.3350/cmh.2024.1096
- Citations
- 3
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Alexion Pharmaceuticals
- Arrowhead Pharmaceuticals
- Sysmex Corporation
- National Institutes of Health
- National Cancer Institute